Item 16. Form 10-K Summary

4K characters. Original on sec.gov · Markdown

Item 16. Form 10-K Summary

​

Not applicable.

​

​

​

SCHEDULE II

AMPHENOL CORPORATION AND SUBSIDIARIES

VALUATION AND QUALIFYING ACCOUNTS

For the years ended December 31, 2024, 2023 and 2022

(Dollars in millions)

​

​

​​​​​​​​​​​​​​
​Balance atCharged to​​Balance at
​​beginning​cost and​Additions​end of
​​of period​expenses​(Deductions)​period
Allowance for doubtful accounts:​​​​​​​​​​​​​
Year ended December 31, 2024​$68.4​$2.6​$(4.5)​$66.5​
Year ended December 31, 2023​63.9​​13.4​​(8.9)​​68.4​
Year ended December 31, 2022​43.5​​20.2​​0.2​63.9​
​​​​​​​​​​​​​​
Valuation allowance on deferred tax assets:​​​​​​​​​​​​​
Year ended December 31, 2024​$46.6​$10.8​$16.2​$73.6​
Year ended December 31, 2023​​42.2​​3.4​​1.0​​46.6​
Year ended December 31, 2022​44.9​​(1.1)​​(1.6)​​42.2​

​

​

​

​

​

​

Signatures

​

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized in the Town of Wallingford, State of Connecticut on the 7th day of February, 2025.

​

​
​AMPHENOL CORPORATION
​​
​​
​/s/ R. Adam Norwitt
​R. Adam Norwitt
​President and Chief Executive Officer

​

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

​

​​
Signature​Title​Date
​​​​​
​​​​​
/s/ R. Adam Norwitt​President, Chief Executive Officer and Director​February 7, 2025
R. Adam Norwitt​(Principal Executive Officer)​​
​​​​​
/s/ Craig A. Lampo​Senior Vice President and Chief Financial Officer​February 7, 2025
Craig A. Lampo​(Principal Financial Officer and Principal Accounting Officer)​​
​​​​​
/s/ Martin H. Loeffler​Chairman of the Board of Directors​February 7, 2025
Martin H. Loeffler​​​​
​​​​​
/s/ David P. Falck​Presiding Director​February 7, 2025
David P. Falck​​​​
​​​​​
/s/ Nancy A. Altobello​Director​February 7, 2025
Nancy A. Altobello​​​​
​​​​​
/s/ Edward G. Jepsen​Director​February 7, 2025
Edward G. Jepsen​​​​
​​​​​
/s/ Rita S. Lane​Director​February 7, 2025
Rita S. Lane​​​​
​​​​​
/s/ Robert A. Livingston​Director​February 7, 2025
Robert A. Livingston​​​​
​​​​​
/s/ Prahlad Singh​Director​February 7, 2025
Prahlad Singh​​​​
​​​​​
/s/ Anne Clarke Wolff​Director​February 7, 2025
Anne Clarke Wolff​​​​

​

​

​

Previous: Item 15. Exhibits and Financial Statement Schedules